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There has been a continuing, worldwide
effort to control the public health and social
burden of cancer. One aspect of this effort
is the identification of agents that cause
cancer in humans and the reduction of
exposure to acceptable levels ofriskby regu-
latory action. Human carcinogens have
been identified with greatest certainty by
epidemiological studies. However, the
rodent bioassay has come into prominence
because using epidemiology to identify
causal agents is feasible only to a limited
extent. Identification ofhuman carcinogens
by rodent bioassay, however, has a number
of important limitations: the most perplex-
ing problem is the uncertainty of whether
all the agents that cause tumors in rodents
do so in humans. A corollary to this prob-
lem is the uncertainty ofwhether the poten-
cy and dose-response relationships are the
same in rodents and humans. There is also
the cost and duration of the National
Toxicology Program (NTP) bioassays, the
gold standard for animal bioassays; the
expense is so high that only a few chemicals
per year can be evaluated. There are many
chemicals in commercial use or in the envi-
ronment that have not been tested, and
thousands ofnew chemicals are synthesized
each year. There is a clear need to improve
the process ofcarcinogen identification not
just so that more chemicals can be evaluat-
ed, but also to achieve a better understand-
ing of human risk. Short-term testing of
chemicals in bacteria and cultured cells con-
tributes valuable information, but such
assays are regarded as ancillary to epidemi-
ology and animal testing because of their
limited biological complexity. For the fore-
seeable future, improvements in identify-
ing potential human carcinogens will come
from improvements in the rodent bioassay.
A useful new tool which has emerged
from developments in molecular biology is
the transgenic rodent. Such animals have
modified genes that cause them to respond
to carcinogens in advantageous ways. This
paper describes the response characteristics
of two of the most promising of these
transgenics, p53+/ and TG.AC, and dis-
cusses ways in which they may be used to
improve carcinogen bioassay.
The p53+/- line responds rapidly to
genotoxic carcinogens, and the TG.AC
line responds rapidly to nongenotoxic car-
cinogens. Positive results in either could
lead to an NTP bioassay modified to focus
on low-level dose response; verification of
carcinogenicity could be substantially
accomplished by the transgenic assay, and
the transgenic assay could provide guid-
ance for dose selection. Thus, the use of
these two transgenic models could accom-
plish several important objectives: 1) accel-
erated testing of environmental chemicals;
2) prioritization of chemicals for NTP
bioassay; and 3) focusing the NTP bioassay
on one primary objective, low-level dose
response, instead of the dual objective of
determining whether an agent is carcino-
genic, which requires administration of
high doses, and at the same time trying to
determine dose-response characteristics at
low doses. Conversely, as experience is
accrued in the use of these transgenics, it
may become evident that with agents that
are clearly positive with structural alert
evaluations, in vitro mutagenicity, and
transgenic bioassays, the full NTP bioassay
is not needed.
Transgenic Mouse Models
Appropriate transgenic mouse lines offer
the opportunity to develop relatively short-
term in vivo models to identify potential
carcinogens and other toxic agents. Such
models include transgenic mice carrying
reporter genes that may serve as targets for
mutagenic events (1,2) or mice carrying
specific oncogenes or inactivated tumor-
suppressor genes that are important factors
contributing to the multistage process of
carcinogenesis (3-5). Mouse lines with
defined genetic alterations that result in
overexpression or inactivation of a gene
intrinsic to carcinogenesis, but that are
insufficient alone for neoplastic conversion,
are promising models for chemical carcino-
gen identification and evaluation. Likely
gene targets for alteration that might result
in this phenotype are 1) the activation (by
mutation) of the c-Ha-ras protooncogene,
which alters signal transduction and growth
control (6), and 2) inactivation of the p53
tumor-suppressor gene, which is critical to
cell cycle control and DNA repair (7-9).
These tumor genes are often mutated
and/or amplified (c-Ha-ras) or mutated
and/or lost (p53) in human and rodent
tumors (10-13).
p53 +/- mice. Mice with only a single
wild-type p53 allele provide a distinct tar-
get for mutagens and are analogous to
humans at risk due to heritable forms of
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cancer, such as the Li-Fraumeni syndrome
(14). The reduction in p53 gene dosage by
this "germline first hit" increases the proba-
bility that a second mutagenic event will
cause either loss of p53 tumor-suppressor
function or gain oftransforming activity by
requiring (at minimum) only a single
mutation (10-13). Mice with inactive p53
genes are viable and, in the hemizygous
state, have a low background tumor inci-
dence for up to 12 months ofage, whereas
nullizygous mice have a higher rate of
spontaneous tumors at sites apparently
determined by the strain's genetic back-
ground (15,16).
We conducted concurrent 6-month car-
cinogenesis studies using male and female
C57BL/6 mice hemizygous for the wild-
type p53 gene together with their homozy-
gous wild-type p53 siblings. We used two
carcinogens that exhibited trans-species car-
cinogenicity (17) (i.e., induced tumors in
both mice and rats), in long-term rodent
bioassays and that were positive in the
Salmonella mutagenesis assay (18-20): p
cresidine (21) and 4-vinyl-i-cyclohexene
diepoxide (VCD) (22). For comparison, we
used two nonmutagenic carcinogens that
were carcinogenic in only one of two test
species: N-methylolacrylamide (NMOA)
(23) and reserpine (24). As a negative con-
trol, we used p-anisidine (25), an analogue
ofp-cresidine, which was positive in the
Salmonella assay and negative in rats and
mice in two-year carcinogenesis studies.
These chemicals represent the opposite ends
of the spectrum of biological activity
observed in rodent bioassays (18-20). To
facilitate this comparison, we used the same
exposure conditions and chemical doses as
used in the 2-year bioassays.
TG.AC mice. TGAC mice carry a v-
Ha-ras oncogene fused to the promoter of
the 4-globin gene (26). The v-Ha-ras trans-
gene has point mutations at codons 12 and
59, and the site ofintegration ofthe trans-
gene confers on these mice the characteris-
tic of genetically initiated skin as a target
for tumorigenesis in the context of the
intensively studied mouse-skin tumorigene-
sis model (27). An important consideration
of the TG.AC mouse model is that the
transgene is not constitutively expressed in
the skin, and the untreated skin appears
normal when compared to the skin of the
wild-type FVB/N parent strain (26,28). In
addition, the spontaneous incidence ofskin
papillomas in the dorsal skin of untreated
mice is very low to zero. Heterozygous or
homozygous TG.AC mice receiving repeti-
tive topical treatment with 12-O-tetrade-
canoylphorbol-13-acetate (TPA) or other
well-described mouse-skin promoters (ben-
zoyl peroxide, mezerein, or methyl ethyl
ketone peroxide) readily develop, as early as
4-6 weeks after treatment, benign squa-
mous papillomas which may progress to
malignancy (26,29).
Our approach to evaluating and using
the TG.AC mice is different from that for
the p53+/- mice. Many of the chemicals
tested initially in TG.AC were used to
characterize the phenotype of the line
rather than to directly assess its use in iden-
tifying carcinogens. As the studies pro-
gressed, the potential use of this line to
identify putative nongenotoxic carcinogens
and to permit extended dose-response
analyses became apparent.
The activities of 20 chemicals have
been evaluated in homozygous female
TG.AC mice using a skin-painting proto-
col. These chemicals represent well-known
mouse skin initiators and promoters
(26,29), specific intermediate metabolites
known to occur in the signal transduction
pathways induced by TPA binding to its
receptor, protein kinase C, and carcinogens
and noncarcinogens identified in the NTP
2-year bioassay. These chemicals include
genotoxic and nongenotoxic carcinogens
and noncarcinogens that represent a spec-
trum of chemicals that have exhibited a
wide range ofbiological activities in the 2-
year NTP bioassays.
We have used the TG.AC mouse
model in both retrospective and prospec-
tive studies to examine its potential to
identify the activity ofpossible carcinogens
and to complement the standard 13-week
prechronic toxicity studies used by the
National Toxicology Program (NTP) to
identify target organs and dose-response
relationships leading to a 2-year rodent
bioassay. While the TG.AC mouse might
seem most appropriate for evaluating the
activity of those chemicals scheduled for a
2-year skin-paint study protocol, our retro-
spective studies with carcinogens identified
in the 2-year NTP bioassays indicated that
chemicals administered in the feed or via
gavage can also exhibit activity in the skin
of topically treated transgenic mice when
using a dose range representative of that
used in the 2-year bioassayprotocol.
Methods
Mice were treated and maintained in accor-
dancewith the NIH Guidelines for Humane
Care and Use and under an institutional,
peer-reviewed animal studyprotocol.
p53 +/- mice. Male and female mice
hemizygous for wild-type p53 (TSG-p53)
and homozygous wild-type siblings were
obtained from GenPharm International
(Mountain View, California). Treatments
began in a staggered fashion at 15-18
weeks of age after a 3-week acclimation
period. Male mice were housed singly, and
female mice were housed in groups; both
were fed a pelleted or powdered defined
diet (#D1001O, Research Diets, New
Brunswick, New Jersey) and water ad libi-
tum. Wild-type sibling and hemizygous
p53 mouse control groups contained 10
mice each and hemizygous p53 treatment
groups contained 15 (low-dose) or 20
(high-dose) mice. Assignment of uneven
numbers was determined by the number of
mice available and unknown effects oftoxi-
cants in these mice. Test chemicals were
administered in the diet daily, by topical
administration (2 times/week; 100 pl ace-
tone vehicle), or by gavage (5 times/week;
corn oil vehicle) for 24 weeks (Table 1).
The mice were held an additional 4-6
weeks to allow tumor development after
interim sacrifices indicated chemical-specif-
ic differences in the rate of appearance of
gross lesions. Clinical observations and
body weights were recorded weekly. All
mice received a gross necropsy and micro-
scopic examination ofgross lesions and tar-
get tissues. Mice were held 4-6 weeks after
cessation of treatment to allow for a stag-
gered termination of the experiments, fol-
lowing determination oftumor progress in
those mice with gross lesions.
TG.AC mice. Groups of 10-15 female
homozygous TG.AC mice, housed 5 per
cage, were first treated when 10 -12 weeks
old. Mice were fed Purina Pico Chow, no.
5058, and water ad libitum. The dorsal
skin at the application site was clipped 1- 2
days before administration ofthe first dose
and as needed throughout the dosing peri-
od. Chemicals were administered topically
to the clipped area with 200 pl of acetone
or 70-95% ethanol 2 to 5 times per week
for 20 weeks. Mice treated concurrently
with the vehicle solvent or 1.25 pg TPA
served as the negative and positive controls,
respectively. Mice were examined weekly
for the development of skin papillomas at
the application site.
Results
p53 +/- mice. Topically administered VCD
induced squamous cell and basal cell carci-
nomas in male and female F344 rats and
male and female B6C3F1 mice in 2-year
bioassays (22,30) that first appeared after
54 weeks of treatment (Table 1). In the
studies described here, both hemizygous
p53 and wild-type male and female mice
showed an apparent dose-related decrease
in body weight gain (not less than 10% of
the concurrent control) throughout the
VCD skin paint study that was reversed
after the treatment period, especially in the
females (data not shown). Microscopic
analysis ofgross lesions revealed that there
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Table 1.Target organ tumor incidence in the 24-weekstudy in C57BL/6 p53-deficient mice and the NTP 103-week study in B6C3F1 hybrid mice
Mouse strain (C57BL/6) Mouse strain(B6C3F,)
Chemical Time" Hemizygous p53 Wild type Dose Timea Wild type
(route: targettissue) Dose (weeks) M F M F (weeks) M F
4-Vinyl-1-cyclohexene diepoxideb 0 mg 24+4 o0/ 0/8 0/5 0/5 0 mg 103 0/50 0/50
(topical: skin) 12.5 mg 24 +4 2/7 0/8 - 5 mg 103 40/50 37/50
25.0 mg 24+4 3/10 3/8 0/5 0/5 10 mg 103 43/50 43/50
p-Cresidine 0% 24 + 2 0/5 0/5 0/5 0/5 0% 103 0/50 0/50
(diet: urinary bladder) 0.25% 24 + 2 4/7 0/8 - 0.25% 103 31/31 44/46
0.5% 24+ 2 9/10 4/10 0/5 0/5 0.5% 103 40/42 41/46
p-Anisidine 0% 24+ 6 0/5 0/5 0/5 0.5 0% 103 Noncarcinogenic
(diet: none) 0.225% 24+ 6 0/8 o0/ - 0.25% 103
0.45% 24+ 6 0/10 0/10 0/5 0/5 0.5% 103
N-Methylolacrylamide 0mg/kg 24+ 6 o0n o0/ 0/5 0/5 0 mg/kg 103 12/50 3/50
(gavage: liver) 25 mg/kg 24 + 6 o0/ 07 -o 25mg/kg 103 17/50 4/50
50 mg/kg 24+6 0/10 0/10 0/5 0/5 50 mg/kg 103 26/50 17/49
Reserpinec 0% 24+6 o0/ 0/8 0/5 0/5 0% 103 0/50 0/50
(diet: M, seminal vesicle; 0.0005% 24 + 6 0/8 o0/ - 0.0005% 103 0/50 7/49
F,mammarygland) 0.001% 24+6 0/10 0/10 0/5 0/5 0.001% 103 0/50 7/48
8Length of exposure plus holding (weeks) before euthanasia and necropsy.
bVCD dosage was administered (mg/mouse) in 200 ml acetone 2>/week or 5 x/week in the 24-week or 105-week studies, respectively; resulting in an equivalent
cumulative weekly dose.
cDue to excessive weight loss and mortality in the high-dose group, survivors were converted to the low-dose feed concentration after 4weeks oftreatment and
maintained in the same cages for the remainder of the study without further loss. Data were also maintained separately because of sustained body weight
depression and clinical observations.
was an apparent dose-related increase in
skin tumors (squamous cell or basal cell
carcinoma or fibrosarcoma) in VCD skin-
painted mice hemizygous for the p53 gene,
but not in the respective p53 +/- vehicle
controls or in the control or high-dose,
homozygous wild-type sibling male or
female mice (Table 1). The incidence of
nodular epidermal hyperplasia appeared to
be a continuum with the development of
squamous cell carcinomas, which may be
significant since carcinomas appeared virtu-
ally in the absence of papillomas.
Repetitive exposure of the skin to carcino-
gens has been shown to result in complete
loss of p53 and malignant skin tumors
without progression through a benign
tumor phase (31,32).
p-Cresidine was mutagenic in the
Salmonella assay and caused urinary bladder
tumors in rats and mice when administered
in the diet (18,21). In the 2-year studies, the
first bladder tumors were observed in
B6C3F1 mice at 40 and 44 weeks of treat-
ment for high-dose male and female mice,
respectively (21) (Table 1). In the current
dose-feed studies, p53 +/- and wild type
mice treated with p-cresidine experienced a
similar short-term transient and dose-related
decrease in body weight gain, which was
greater in males than in females of either
mouse line and was similar to that observed
in the 2-year studies. It is important that
both p53 +/- and wild-type mice exhibited
similar systemic toxicity, but the latter did
not develop tumors. After 6 months of
exposure and a 2-week holding period,
microscopic analysis ofgross lesions revealed
an apparent dose-related increase in urinary
bladder transitional cell carcinomas in male
and female p53 hemizygous mice, but not
in the p53 +/- controls or in the high-dose,
homozygous wild-type siblings (Table 1).
Tumors were grossly observed as thickened
bladder walls or large masses, which fre-
quentlywere associated with hydronephrosis
due to bladder occlusion. These characteris-
tics were similar to the tumors induced in
the B6C3F1 mice used in the 2-year bioas-
say. Microscopically, the carcinomas were
invasive masses composed of markedly
anaplastic cells and/or cells exhibiting squa-
mous differentiation. In one high-dose p53
+/- female, a squamous papilloma of the
bladder mucosa was observed. Deaths relat-
ed to tumor induction that occurred during
the study (Table 2) were especially frequent
in male micehemizygous forwild-type p53.
p-Anisidine, an analogue ofp-cresidine,
was mutagenic in the Salmonella assay and
was not carcinogenic to male or female
F344 rats or B6C3F1 mice in 2-year dosed-
feed studies (25). In those studies, the dose
levels used induced bodyweight depression
without an increase in mortality in the
treated groups relative to the controls. In
the present dosed-feed study, p-anisidine
(administered equimolar top-cresidine) did
not induce any significant clinical observa-
tions or depressed bodyweight gain relative
to the control groups (Tables 1 and 2).
However, 5 of 15 low-dose p53 +/- mice
died of unexplained causes during the
study. None ofthe high-dose p53 +/- mice
were affected. No gross lesions or micro-
scopic lesions in the urinary bladder were
observed after 24 weeks ofdietary adminis-
tration and a 6-week holding period.
NMOA was nonmutagenic in the
Salmonella assay, although it contains a
chemical structural alert indicating elec-
trophilic potential and was carcinogenic to
mice in 2-year bioassays when administered
by oral intubation (18,23) (Table 1). In the
2-year bioassays, NMOA-treated B6C3F1
male and female mice exhibited an increase
in bodyweight gain relative to controls and
increased incidences of tumors in the
Harderian gland, liver, lung, and ovary. In
the studies with transgenic mice, NMOA
depressed body weight gain in male mice
(greatest in high-dose, wild-type siblings)
and slightly increased body weight gain in
female mice (data not shown). Mortality
was slightly increased in high-dose male and
female mice hemizygous for p53, but no
induced tumors were observed (Table 2).
Reserpine was not mutagenic in the
Salmonella assay, but in the 2-year dosed
feed studies, it induced mammary gland
tumors in B6C3F1 female mice (18,24)
(Table 1). In these transgenic mouse stud-
ies, reserpine administered at 0.001% of
the diet to p53 +/- mice resulted in lethar-
gy, tremors, piloerection, and severe weight
loss and death (Table 2), requiring imme-
diate reduction of the high dose after 4
weeks of treatment to the lower dose level
for the duration ofthe study in thehemizy-
gous p53 mice to prevent further deaths.
No tumors or gross toxic lesions were
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observed in high-dose mice converted to
the low dose, or in low-dose mice that sur-
vived to the end ofthe study.
TGAC mice. In the retrospective stud-
ies, seven of eight chemicals were correctly
identified as carcinogens or noncarcinogens
when administered via the skin paint proto-
col in TG.AC female mice (Table 3).
Benzene (18,33-35), a proven human car-
cinogen and a multisite, trans-species
rodent carcinogen, readily induced papillo-
mas in 70% of the transgenic mice by 10
weeks ofexposure. Mirex (36), a nongeno-
toxic liver carcinogen when administered in
the feed to rats, induced papillomas, which
were observed as early as 7 weeks. In the
NTP studies, o-benzyl-p-chlorophenol (37),
a nonmutagenic carcinogen, caused kidney
tumors in maleB6C3FI mice when admin-
istered by oral intubation (gavage) (Table
3). When administered topically as a pro-
moter (3 mg, 3 times/week) for 50 weeks
following an initiating dose of dimethyl-
benz[a]anthracene, o-benzyl-p-chlorophenol
induced a low incidence of papillomas (2
papillomas/mouse) in 36% of the treated
female mice (38). Topically applied o-ben-
zyl-p-chlorophenol (3 mg, 3 times/week for
20 weeks) induced papillomas in 80% of
the treated TG.AC mice, with an overall
Table2. Incidence ofmortality during the in-life portion ofthe bioassay before termination
Mouse strain
Time Hemizygous p53 Wild type
Chemical Dose (weeks) M F M F
4-Vinyl-1-cyclohexene diepoxideb 0 mg 24 + 4 o0/ 0/8 0/5 0/5
12.5mg 24+4 o0/ 2/8 -
25.0 mg 24+4 2/10 0/10 0/5 0/5
p-Cresidine 0% 24 + 2 0/5 1/5 0/5 0/5
0.25% 24+ 2 2/8 0/7 -
0.5% 24+ 2 7/10 2/10 0/5 0.5
p-Anisidine 0% 24+ 6 0/5 0/5 0/5 0.5
0.225% 24+ 6 2/7 3/8 -
0.45% 24+6 0/10 0/10 1/5 0/5
N-methylolacrylamide 0 mg/kg 24+6 0/7 o0/ 0/5 0/5
25mg/kg 24+6 1/7 1/7 -
50 mg/kg 24+6 2/10 2/10 0/5 1/5
Reserpinec 0 % 24+ 6 on 0/8 0/5 0/5
0.0005 % 24+6 1/8 1/7 -
0.001 % 24+6 7/10 6/10 1/5 1/5
aLength of exposure plus holding (weeks) before euthanasia and necropsy.
bVCD dosage was administered (mg/mouse) in 200 ml acetone 2x/week or 5x/week in the 24week or 105
weekstudies, respectively; resulting in an equivalent cumulative weekly dose.
cDue to excessive weight loss and mortality in the high dose group, survivors were converted to the low
dose feed concentration after 4 weeks oftreatment and maintained in the same cages for the remainder
ofthe studywithoutfurther loss. Data were also maintained separately because ofsustained bodyweight
depression and clinical observations.
Table 3. Retrospective evaluation of NTP chemicals for activity inTG.ACtransgenic mice
NTP bioassay TG.AC skin paint
Maximum dose Ratc Mousec Avg. papillomas/ %Mice with
Chemical SALa Routeb Rat Mouse M F M F LEDd TTFPe mouse" papillomasf Activity
Benzene - G 200 100 + + + + 200pl,2x/week 5 7.4 77 +
Benzethomium chloride - SP 1.5, 1.5, - - - - 60 pg, 8 0.55 22
Sxweek 5x/week 5x/week
o-Benzyl-p-chlorophenol - G 240 480 - E (K) + (K -
SP ND 3mg/mouse, ND ND +9 +9 3mg, 7 3.0 80 +
3x/week 3x/week
(50weeks)
2-Chloroethanol + SP 100, 15, - - g - 20mg, 10 0.10 11
5x/week 5x/week 5x/week
p-Cresidine + F 1.0 0.46 +(UB) +(UB) +(UB) +(UB) 80pg, 6 5.0 58 +
2x/week
Ethyl acrylate - G 200 200 +(S) +(S) +(S) +(S) 30mg, 15 0.6 50
3x/week
Mirex - F 0.005 ND +(L,AG)+(L, HS) ND ND 54.5 pg, 7 12 70 +
3x/weekh
Phenol - W 0.5 0.5 - - - - 3.0mg, 7 0.20 0.16
2x/week
ND, not done.
aSAL Salmonella mutagenicity results provided by E. Zeiger, NationalToxicology Program.
bRoute of administration of test chemical. G, oral gavage, dose in mg/kg, given 5x/week; SP, skin paint, dose is in mg/kg except where otherwise indicated; F,
feed, dose in %; W, drinking water, dose in %.
CF344 rats and B6C3F1 mice except as noted. Tumor sites in parentheses: K, kidney; UB, urinary bladder; S, stomach; L, liver;AG, adrenal gland; HS, hematopoietic
system. E, equivocal results.
dLED, lowest effective dose per mouse that induced papillomas atthe site ofapplication or highest "no effect' dose administered.
eTTFP,time (weeks) to firstobservation of a skin papilloma in any mouse ofthatdose group.
fAt 20weeks.
9CD-1 mice.
hData from a collaborative studywith R. Smart, North Carolina State University.
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incidence of3 papillomas/mouse (Table 3).
p-Cresidine, the genotoxic urinary bladder
carcinogen (18,21) described above in p53
+/- mouse studies, not only induced papil-
lomas in TG.AC mice, but showed systemic
effects by causing the same preneoplastic
lesions in the bladder epithelium that were
observed in B6C3F1 mice. Benzethonium
chloride (39) and phenol (18,40), both
nongenotoxic noncarcinogens, and 2-
chloroethanol (18,41), a genotoxic noncar-
cinogen, were inactive in the TG.AC mice.
Ethyl acrylate, a nongenotoxic carcinogen
(19,42) induced only forestomach tumors
in the 2-year bioassay, a consequence of
gavage exposure and cell proliferation
(43-45). Ethyl acrylate was inactive in
TG.AC mice, and no gross systemic effects
were observed at the end of the 20-week
skin-paint study that had induced chronic
epidermal hyperplasia at the application site
(Table 3). It is noteworthy that another
trans-species forestomach carcinogen,
diglycidyl resorcinol ether (19,46), was also
inactive in a long-term skin paint study in
female Swiss mice (4.
Four chemicals undergoing skin-paint-
ing studies in NTP bioassays were evaluated
prospectively for activity in TG.AC mice
using dose ranges representative of those
used in the 2-year studies (Table 4). Lauric
acid diethanolamine (NTP studies in
progress) and methyl ethyl ketone peroxide
(48) readily induced papillomas as early as 4
and 5 weeks, respectively (Table 4). No
papillomas were induced by 20 weeks of
treatment with diethanolamine (NTP stud-
ies in progress) or triethanolamine (49).
The accuracy of these predictive studies
await the outcome ofthe NTP bioassays.
Discussion
Hemizygous p53 mice, but not their
homozygous wild-type sibling controls,
developed tumors after treatment with two
model mutagenic carcinogens, but not with
two model nonmutagenic carcinogens or
with a mutagenic noncarcinogen. Tumors
appeared much sooner, but at the same
organ sites, in the hemizygous p53 mice as
they did in B6C3F1 mice in the 2-year
bioassays with the mutagenic carcinogens.
These limited data suggest that the hemizy-
gous p53 mice may exhibit a specificity of
response for mutagenic carcinogens as well
as increased sensitivity when compared to
their normal, wild-type littermates.
However, neither ofthe nonmutagenic car-
cinogens induced tumors in their expected
target tissues in either hemizygous p53 or
homozygous wild-type sibling mice when
administered for 6 months by the same
route used in 2-year bioassays. These short-
term bioassay results are consistent with the
2-year NTP bioassays for the mutagenic
carcinogens, indicating that the C57BL/6
strain responded similarly to the B6C3F1
hybrid. Although the number ofmice used
in these studies was small compared to
long-term toxicology studies, these data
indicate that these mice may have increased
susceptibility to mutagenic carcinogens
(15,16,32) and that mutagenic chemicals
are required to initiate the carcinogenic
responses observed.
The skin-paint studies in the TG.AC
transgenic mice indicate that the model can
complement the standard NTP 13-week
subchronic bioassays that are used to identi-
fypotential target organ sites for toxiceffects
or neoplasia in the 2-year bioassay.
Furthermore, the model is sensitive to
chemicals that do not necessarily target the
skin when administered by other routes of
exposure. Some major advantages of this
model are that the skin-tumor response can
bevisiblyobserved and inducedwithin a 20-
week dosing regimen; furthermore, the dos-
ing protocol (e.g., dose frequency per week)
can be varied according to the toxicityofthe
chemical. The target organ site, the dorsal
skin, is normal until stimulated by a series of
chemically induced events that lead to the
induction of skin papillomas (26,29l. The
latency period is short, with the first tumors
appearing as early as 5 weeks and usually by
10 weeks when using a 20-week dosing pro-
tocol. Further, in every instance where the
treated mice were observed an additional
10-20 weeks after cessation of dosing, a
subpopulation of the papillomas progressed
to malignancy. Other important considera-
tions are that the life span ofhomozygous
TG.AC mice is well over a year, and the
sporadic papilloma incidence at the target
site, dorsal skin, is very low to zero in
untreated orvehicle-control mice. Untreated
TG.AC mouse skin has normal morphologi-
cal and physiological characteristics that are
maintained throughout the mouse's life
span. The transgene is not constitutively
expressed at the target sites, but is expressed
in association with the proliferative cell
component observed in early papillomas
(28). From these limited data, the TG.AC
mouse model appears to identify genotoxic
and nongenotoxic carcinogens and to dis-
criminate a high proportion of carcinogens
and noncarcinogens.
Dose and Dose-Rate Studies
Another potential advantage of the trans-
genic models is their capability of provid-
ing dosimetric data. A major controversy in
toxicology is the nature of the dose
response derived from rodent bioassays.
Due to the variable potency and toxicity of
chemicals and the variable and often high
rate of site-specific sporadic tumors (50),
few bioassays produce data that can be
appropriately evaluated at relatively low
doses. For example, benzene induced a
broad spectrum of tumors in a relatively
high proportion of mice in the rodent
bioassay (33,35). When all significant sites
of tumorigenesis were combined, even the
low dose (20 mg/kg body weight) induced
tumors in approximately 60% ofmale and
female B6C3F1 mice. As shown in Figure
1, these results suggest that the response at
all doses could represent the upper portion
of a dose-response curve, and the pattern
was similar for papillomas induced by ben-
zene in TG.AC mice. However, the
prospects that lower doses in B6C3F1 mice
could produce data sufficient to allow the
true shape ofthe dose response to be deter-
Table 4. Prospective evaluation of NTP chemicals for activity in TG.ACtransgenic mice
TG.AC skin paint
NTP skin paintbioassay(maximum dose)a Avg.papillomas! % Mice with
Chemical SALb F344 rat B6C3F1 mouse LED (mg)c TTFPd mouse papillomase Activity
Diethanolamine - 64 160 20, 5x/week - 0.0 0.0
Lauric acid diethanolamine - 100 200 10, 5x/week 4 6.1 92 +
Triethanolamine - 250 2000 30, 5x/week 7 0.17 8.3
Methyl ethyl ketone peroxide -,+ 3.6 mg/rat 3.6 mg/mouse 5.0, 2x/week 5 50 100 +
aResults pending completion of 2-year bioassay study and peer review. Doses in mg/kg, except for methyl ethyl ketone peroxide, which was administered five
times/week.
bSAL, Salmonella mutagenicity results provided by E. Zeiger, National Toxicology Program.
CLED, lowest effective dose that induced papillomas atthe site ofapplication or highest "no effect" dose administered.
dTTFP, time (weeks) to first observation of a skin papilloma in any mouse ofthat dose group.
eAt 20 weeks.
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mined, even by extrapolation, is quite
unlikely because of the high proportion of
control mice that developed tumors at
many of the same sites as the benzene-
exposed mice by the end of the 104 week
study. Because the frequency of sponta-
neous tumors increases with time, the dis-
tinction between induced and spontaneous
tumors becomes more difficult to discern.
The principal attribute of the two trans-
genic mouse lines described here is that
induced tumors develop within a time
frame in which the spontaneous tumor
incidence is effectively zero, thus reducing
the confounding effects observed in an
agingpopulation.
The benzene study was repeated in
TG.AC mice using doses as low as 75
pl/week/mouse. The high dose portion of
the dose-response pattern, similar to that
for the bioassay, was observed again, but it
is noteworthy that the response curve also
extended into the low-dose range (Fig. 2).
These results suggest that it will be possible
to compare the dose response of various
chemicals, including known human car-
cinogens, and to study dose-rate effects of
chemicals, including time-to-tumor analy-
sis, which are critical (51). Further, in the
case ofthe p53 +/- mouse line, it is possible
to design molecular dosimetry studies
because mutational spectra of the single
functional wild-type p53 alleles may be
determined (12).
Identification ofPresumptive
Carcinogens
Although large numbers of new chemicals
are continually being synthesized for poten-
tial use, they need not all be subjected to a
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complete rodent bioassay. Over the past
three decades, information has been devel-
oped in the characterization ofthe biologi-
cal effects ofmost major structural classes of
chemicals. It is possible to use available data
to predict the relative toxicity or carcino-
genicity ofmany untested chemicals.
The most predictive mechanistic deter-
minant for chemical carcinogenicity is
mutagenic potential (52). It has been rec-
ognized for many years that chemicals that
demonstrate mutagenicity in vitro are also
carcinogenic to rodents (34,53). An exten-
sive evaluation of the association between
mutagenicity and carcinogenicity of 114
chemicals that were subjected to rodent
carcinogenicity bioassays showed that
approximately 70% of the chemicals that
were mutagenic in the Ames Salmonella
mutagenicity assay were rodent carcinogens
(53,54). Based on this relationship, muta-
genicity, as well as other information relat-
ing to chemical structure and toxicity, were
used to predict carcinogenic potential in
two rodent species (55). Forty-four chemi-
cals that were undergoing bioassays, for
which the results were not yet available,
were the focus of an effort to demonstrate
that chemical structure, mutagenicity, and
data from subchronic toxicity studies were
sufficient to prospectively identify many
potential carcinogens with a high degree of
certainty. The principal results ofthe effort
showed that a chemical of unknown car-
cinogenicity could be predicted to be in
one of three possible categories: probably
carcinogenic, probably noncarcinogenic, or
ofuncertain activity (56). All ofthe chemi-
cals that induced trans-species carcinogenic
effects were correctly predicted. Trans-
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species rodent carcinogens demonstrate
similar properties (mutagenicity and toxici-
ty) ofproven human carcinogens and rep-
resent a more proximate risk to human
health than species-restricted carcinogens
(17). The overall specific predictions were
75% concordant with the results of the
rodent bioassays; the least success occurred
with the chemicals that produced uncertain
effects in the bioassay (i.e., equivocal evi-
dence ofcarcinogenicity or single-site, sex-
specific, and species-specific effects).
Integration of data on chemical structure,
mutagenicity, and systemic toxicity tended
to overpredict carcinogenicity (i.e., 7 of 10
missed predictions were for carcinogenici-
ty) (56), but any predictive strategy should
be risk-adverse, that is, involve principally
false-positive errors (57-60).
It also became clear from this exercise
that while mutagenicity is a major mecha-
nistic determinant, this property is neither
sufficient nor necessary for carcinogenicity.
Approximately one-third of the nonmuta-
genic chemicals tested in bioassays have
shown some evidence of carcinogenicity.
Conversely, approximately one-third ofthe
chemicals that were mutagenic in vitro
were not carcinogenic in the bioassay
(52,54). Thus, mechanism-based predic-
tions were the most accurate for potent car-
cinogens and for chemicals that were clear-
ly noncarcinogens. Use ofthis information
alone could reduce significantly the depen-
dence on rodent bioassays. However, iffur-
ther improvements in the prediction
process can be achieved, it should be possi-
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Figure 1. Comparison of 2-year bioassay and 20-week dose-reponse studies for cumulative tumor burden
in benzene-exposed mice. The graph shows tumors at all sites identified as resulting from chemical expo-
sure in B6C3F1 mice in the 2-year bioassay and papilloma incidence in TG.AC mice exposed to benzene.
The doses represent gavage exposure (mg/kg) in B6C3F1 mice or skin paint exposure (pl) in TG.AC mice
for 20weeks.
Figure 2. Benzene dose response. Groups of 10
TG.AC female mice exposed for 20 weeks to ben-
zene via skin paint. Papillomas were counted
weekly and the maximum countable limit was 30
papillomas/mouse.
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ble to reduce the uncertainty about the car-
cinogenic potential of nonmutagenic
chemicals and reduce the number of false
positives, i.e., in vitro mutagens that are
incorrectly predicted to be carcinogens.
The major impediments to successful pre-
dictions are the relatively weak chemicals
that induce single-site, species-specific, or
equivocal carcinogenic effects, which are
generally the consequence of the use of
inbred rodent strains (1/).
Strategy for the Use ofTransgenic
Mice
Based on the responses of the p53 +/- and
TG.AC mouse lines to specific chemical
treatment regimens discussed here, we pro-
pose that these lines can be used selectively
in conjunction with the 2-year bioassay to
confirm predictions based on the aggregate
of structure-activity relationships, in vitro
genotoxicity, and systemic toxicity, ulti-
mately reducing the number of chemicals
(and mice) that must be subjected to 2-year
rodent bioassays. The strategy is depicted
in the decision-tree scheme outlined in
Figure 3; a key element is the use of p53
+/- mice for the verification of predicted
mutagenic carcinogens.
Few studies have specifically investigat-
ed the effects of environmental chemicals
on the p53 tumor-suppressor gene in wild-
type or genetically altered mice
(16,29,61,62), and p53 mutations in
experimentally induced rodent tumors have
not been observed as frequently as in
human tumors. This difference may be due
to the methods ofobservation, tumor type,
the degree of progression of the neoplasia,
etc. Hemizygous p53 mice that lose the
function of the remaining wild-type allele
may allow a decreased latency through an
increased rate ofprogression to malignancy
without altering tumor multiplicity (325 or
the tissue specificity ofa chemical carcino-
gen. Trans-species carcinogens may involve
chemical interaction with highly conserved
genes involved in regulation ofcell prolifer-
ation or differentiation (/7,17,63,64).
Interaction of mutagenic carcinogens with
highly conserved genes in the genome may
explain, at least partly, why hemizygous
p53 mice exhibit a shortened latency while
retaining tissue specificity. In addition,
genomic stability may decrease with loss of
both wild-type p53 alleles (7,63,64), possi-
bly because of the loss of the ability to
arrest the cell cycle to allow sufficient time
for DNA repair and/or to induce apoptosis
(8,65,66).
Although the number of chemicals
evaluated in the p53 +/- line are limited,
the results to date support further evalua-
tion of the proposal of using this line to
identify or verify mutagenic carcinogens.
Because ofthe relatively rapid induction of
tumors and the high proportion of the
mice responding, we propose that chemi-
cals with properties that predict mutagenic-
ity and carcinogenicity be tested in this
model before conducting a 2-year bioassay.
Data relevant to potential target tissues and
dose-response patterns can be obtained
from a transgenic mouse study that can be
conducted within 6-month exposure peri-
ods. The uniform sensitivity ofthe animals
allows fewer mice to be used per dose
group, and the absence of spontaneous
tumors allows for a more categorical deter-
mination ofcarcinogenic potential at lower
Toxicity, in general, as indicated by the empirically determined maximum tolerated dose, increases for
mutagenic carcinogens compared to nonmutagenic carcinogens (17).
doses. Ifthe toxicity ofthe chemical is not
known from other studies, preliminary esti-
mates can be made efficiently using wild-
type nontransgenic siblings with the same
genetic background. Application of the
maximum tolerated dose (67) can be obvi-
ated because an extended dose-response
characterization is possible. With a reduc-
tion in duration and overall cost, the trans-
genic mouse experiment may be repeated
for verification or to determine additional
doses required for dose-response character-
ization, which is rarely done with the 2-
year bioassays.
The second component ofthe strategy is
the use ofthe TG.AC mouse line. Although
mutagenicity is the mechanistic determinant
most clearly defined for a presumptive car-
cinogen, it is possible that some chemicals
may not induce tumors through mutations
but through epigenetic pathways. Therefore,
chemicals that are not carcinogenic in the
p53 +/- mouse line might still possess poten-
tial for nonmutagenic carcinogenicity. Since
the TG.AC mouse line has shown sensitivity
to nonmutagenic carcinogens and tumor
promoters, a chemical actingvia a nonmuta-
genic mechanism may be detected in these
transgenic mice. Further, chemicals that
were not tumorigenic in either line may be
considered to be presumptive noncarcino-
gens or in the conventional category of
"generally recognized as safe." A crucial
question iswhether 2-year orlifetime rodent
bioassays will still be required to declare a
chemical noncarcinogenic. Chemicals that
are negative in both of these transgenic
mouse lines may still require a complete
rodent bioassaybecause the preliminary data
indicate that neither transgenic model will
detect all carcinogenic activity in rodents. In
particular, nonmutagens that induce single-
site carcinogenic effects would not be
expected to be effective in the transgenic
models. Such highly specific carcinogenic
effects are unlikely to be predictable by any
foreseeable strategy because the actions of
such chemicals are the product of highly
specific genetic effects or the interaction
with specific gene products (17). It is plausi-
ble that the studyofsuch chemicals in other
transgenic models may provide insights into
their modes of action, but the transgenic
mouse lines proposed in this strategy will
most likely fall to identify many site-specific
carcinogens. The preliminary results with
ethyl acrylate support this interpretation.
Rodents are used as surrogates for humans,
and it is essential to note that the aim is to
identify carcinogens that may be predicted
to be carcinogenic for humans. Several sin-
gle-site responses in rodents now appear to
be very unlikely to predict similar risk for
humans (61,6$).
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Validation of this strategy can be
accomplished by two approaches: one is
retrospective, the other prospective. The
retrospective approach, taken in the valida-
tion of in vitro or short-term test methods,
has typically involved testing well-defined
carcinogens. This approach led to overcon-
fidence in the value of many short-term
assays which, when they were more fully
characterized for response to noncarcino-
gens, were found to lack sufficient specifici-
ty to be useful (52,53). While the selective
testing of known carcinogens and noncar-
cinogens in the TG.AC and p53 +/- mouse
lines is necessary, there is also the opportu-
nity for a more direct and objective valida-
tion. This prospective approach involves
testing chemicals that are currently under-
going long-term bioassays. By providing
results, both qualitative and quantitative,
before the outcome ofthe 2-year bioassay is
known, even implicit investigator bias
(such as in the selection of chemicals) is
eliminated. We have implemented this
approach with the TG.AC mouse line by
prospectively testing four chemicals under-
going 2-year rodent bioassays (Table 4). It
is important to emphasize that the hypoth-
esis being tested by this type ofvalidation is
that these transgenic models will preferen-
tially identify trans-species carcinogens and
noncarcinogens. The TG.AC mouse line is
responsive to a number of tumor promot-
ers, but this is not a useful distinction in
the context of the rodent bioassay. The
principle of trans-species effects (17)
should apply, since chemicals that can pro-
mote only in a single-species or strain are
subject to the action ofgene(s) or chemical
specificity that limit their carcinogenic (or
promotion) potential (67). Thus, while the
TG.AC mouse line may identify chemicals
with the capacity to promote tumor devel-
opment in a mouse two-stage assay, its use
is aimed principally at the detection of
nonmutagenic carcinogens, for the verifica-
tion of mutagenic carcinogens positive in
the p53 +/- mouse line and for
dose-response data.
This strategy can also be applied to
problems associated with the development
ofnew products for commercial or medici-
nal uses. Widespread application of the
Salmonella mutagen assay has resulted in a
marked decrease in the development of
new products or chemicals that are positive
in that assay. However, approximately 30%
of such chemicals have not been carcino-
genic when tested in 2-year bioassays.
Because most mutagens are carcinogenic
and because ofthe economic and regulato-
ry risks (i.e., what information is needed to
override a positive result in a Salmonella
mutagenesis assay), the development of
such products may be abandoned early.
The use ofthe proposed predictive strategy
outlined here can result in the identifica-
tion of such "mutagenic noncarcinogens"
and provide a scientific and economic justi-
fication for further development or for a
more informed decision to conduct a costly
bioassay to verify the lack of carcinogenic
potential.
This strategy is not presented as a
panacea to all of the public health issues
associated with environmental carcinogens
and risk assessment. It represents the use of
new experimental tools to search for
answers to such problems, and it can be
objectively challenged and validated using
ongoing and future bioassays. The strategy
provides a mechanistic basis forjudging the
carcinogenicity ofchemicals and for better
defining the specific chemical-gene interac-
tions that induce and promote the develop-
ment ofcancers.
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